.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,230,030

« Back to Dashboard

Details for Patent: 7,230,030

Title:Derivatives of 3,3-diphenylpropylamines
Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
Inventor(s): Meese; Claus (Monheim, DE), Sparf; Bengt (Trangsund, SE)
Assignee: Schwarz Pharma AG (Monheim, DE)
Filing Date:Jan 27, 2004
Application Number:10/766,263
Claims:1. A 3,3-Diphenylpropylamine having the formula I: ##STR00052## wherein R and R' are independently hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted benzyl, or allyl; with the proviso that at least one of R' and R is not hydrogen, and the proviso that R' is not methyl or benzyl when R is hydrogen, and R is not ethyl when R' is hydrogen, X represents a tertiary amino group of formula Ia ##STR00053## wherein R.sup.8 and R.sup.9 represent C.sub.1-C.sub.6 alkyl groups, which may be the same or different and which together contain at least three carbon atoms, or R.sup.8 and R.sup.9 may form a ring together with the amine nitrogen, A represents hydrogen (.sup.1H) or deuterium (.sup.2H), and their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical isomers, the racemic mixture and the individual enantiomers.

2. The 3,3-Diphenylpropylamine of claim 1, wherein X is ##STR00054##

3. A 3,3-Diphenylpropylamine having the formula VI: ##STR00055## wherein A represents hydrogen (H) or deuterium (.sup.2H), and their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical isomers, the racemic mixture and the individual enantiomers, and wherein one of R.sup.10 or R.sup.11 is selected from C.sub.1-C.sub.6 alkyl, allyl, or benzyl, and the other represents hydrogen, with the proviso that R.sup.11 is not methyl or benzyl when R.sup.10 is hydrogen, and R.sup.10 is not ethyl when R.sup.11 is hydrogen.

4. The 3,3-Diphenylpropylamine of claim 3 selected from the group consisting of: (.+-.)-2-(3-diisopropylamino-1-phenylpropyl)-4-methoxymethyl-phenol, (.+-.)-2-(3-diisopropylamino-1-phenylpropyl)-4-ethoxymethyl-phenol, (.+-.)-2-(3-diisopropylamino-1-phenylpropyl)-4-propoxymethyl-phenol, (.+-.)-2-(3-diisopropylamino-1-phenylpropyl)-4-isopropoxy-methylphenol, (.+-.)-2-(3-diisopropylamino-1-phenylpropyl)-4-butoxymethyl-phenol.

5. A 3,3-Diphenylpropylamine having the formula VII': ##STR00056## wherein R is C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.10 cycloalkyl, substituted or unsubstituted benzyl, or allyl; X represents a tertiary amino group of formula Ia ##STR00057## wherein R.sup.8 and R.sup.9 represent non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein R.sup.8 and R.sup.9 may form a ring together with the amine nitrogen, Y and Z independently represent O, S or NH, A represents hydrogen (.sup.1H) or deuterium (.sup.2H), n is 0 to 12, and their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical isomers, the racemic mixture and the individual enantiomers.

6. The 3,3-Diphenylpropylamines of claim 5, wherein X is ##STR00058##

7. A pharmaceutical composition comprising a 3,3-diphenylpropylamine according to any one of claims 1-6 and a pharmaceutically acceptable carrier.

8. A process for the production of ethers according to claim 3, wherein R.sup.11 is hydrogen, which comprises reacting a compound of the formula ##STR00059## with an alcohol R.sup.10--OH in the presence of a catalyst.

9. A process for the preparation of ethers of formula VI: ##STR00060## wherein A represents hydrogen (.sup.1H) or deuterium (.sup.2H), and their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical isomers, the racemic mixture and the individual enantiomers, and wherein one of R.sup.10 or R.sup.11 is selected from C.sub.1-C.sub.6 alkyl, allyl, or benzyl, and the other represents hydrogen, with the proviso that R.sup.11 is not methyl or benzyl when R.sup.10 is hydrogen, and R.sup.10 is not ethyl when R.sup.11 is hydrogen; wherein the process comprises acid or base treatment, in the presence of at least one alcohol selected from R.sup.10OH and R.sup.11OH, of a compound selected from ##STR00061## wherein R.sup.10 is hydrogen, ##STR00062## wherein R.sup.12 is hydrogen and R.sup.13 represents a C.sub.1-C.sub.6 alkoxycarbonyl group or ##STR00063## wherein R.sup.4 and R.sup.5 independently represent hydrogen, C.sub.1-C.sub.6 alkyl, substituted or unsubstituted aryl, benzyl or phenoxyalkyl wherein the alkyl residue has 1 to 4 carbon atoms or R.sup.4 and R.sup.5 form a ring together with the amine nitrogen, and (f) benzylic acylates selected from ##STR00064## wherein R.sup.1 is hydrogen, C.sub.1-C.sub.6 alkyl or phenyl, and R.sup.2 represents hydrogen, C.sub.1-C.sub.6 alkyl or phenyl, with the proviso that R.sup.1 and R.sup.2 are not identical.

10. A process for the preparation of ethers of formula VI according to claim 3, which comprises treating a compound of the formula ##STR00065## with an alkylating agent selected from alkyl halides, alkyl sulphates and alkyl triflates, said alkyl group having 1 to 6 carbon atoms.

11. A method of antagonizing a muscarinic receptor, the method comprising contacting the receptor with a compound according to any one of claims 1-6.

12. A method of treating a disease in a mammal that is amenable to treatment by antagonizing muscarinic receptors in the mammal, the method comprising administering an amount of a composition according to claim 7 effective to diminish or eliminate symptoms of the disease.

13. The method according to claim 12 wherein the disease is urinary incontinence.

14. The method according to claim 13 wherein the mammal is a human.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc